



To,

Date: 14<sup>th</sup> February 2026

The Listing Compliance Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai- 400051

**Subject:** Response to Exchange email dated 13<sup>th</sup> January 2026 and 5<sup>th</sup> February 2026 for the requirement of Clarification for Financial results.

Dear Sir,

This is in reference to your mail dated 13<sup>th</sup> January 2026 and 5<sup>th</sup> February 2026 seeking certain clarifications for Financial results from the Company. Please find below our point-wise response for your kind perusal and records:

**Query 1:** Financial results submitted is not as per format prescribed by SEBI- a. Figures of Half Year ended March 2025 not provided. b. Figures of EPS missing in PDF c. Statement on Utilisation of Issue Proceeds not signed by Auditor.

**Response:** Pursuant to receipt of your query and immediately upon identification of the discrepancy, the Company has now submitted the financial results in the format prescribed by SEBI, duly incorporating the figures for the half year ended March 2025. The revised financial results have been prepared strictly in accordance with the applicable SEBI regulations and prescribed reporting format.

Further, with regard to your observation on missing figures of Earnings Per Share (EPS) in the PDF, we confirm that the same have now been duly incorporated in the revised submission.

Additionally, with respect to the observation that the Statement on Utilisation of Issue Proceeds was not signed by the Auditor, we clarify that the duly signed Certificate from the Auditor has now been submitted in compliance with the applicable requirements.

**Query 2:** Financial results not submitted within 30 minutes or 3 hours from the end of board meeting (as may be applicable).

**Response:** We wish to submit the following bona-fide and unavoidable reasons for the delay:

1. One of our Directors, **Narendra Tanwar**, who is also the Hospital's senior Cardiologist, was required to urgently attend to a critical cardiac emergency case just before the scheduled Board Meeting, the Board Meeting could commence only at 10:00 PM instead of the planned time due to unavoidable commitments of key Directors and the Audit

**Maitreya Medicare Limited**

Address : Nr. Someshwara Char Rasta, UM Road, Surat, Gujarat - 395007.

Ph. : 0261-2299000 | Reception : +91 82382 29900 | Email : maitreyamedicare@gmail.com

CIN : L24290GJ2019PLC107298



Committee. The meeting then concluded at 11:30 PM after detailed discussions and approval of the financial results.

Given the late-night conclusion of the meeting and the requirement of coordinating with the finance team, auditors and authorised signatory immediately thereafter, the process of preparing and uploading the documents on the Exchange portal took additional time, resulting in the delay beyond the 30-minute window.

1. At the time of uploading the financial results on the Stock Exchange Portal, our team experienced an unexpected system error.
  - The portal repeatedly failed to accept the PDF attachments of the financial results.
  - Multiple attempts were made using different systems and internet connections.
  - The issue was resolved only after system cache clearing and re-authentication.

This resulted in an unintended delay in filing despite the documents being ready immediately upon conclusion of the Board Meeting.

We submit that the delay was unintentional, technical in nature, and occurred despite having all documents ready for filing immediately upon conclusion of the Board Meeting.

We assure you that:

- We have taken corrective steps,
- Strengthened our IT and filing process, and
- Implemented internal controls to avoid such delays in future.

With reference to the above-mentioned matter, we would like to inform you that the Company has already submitted the requisite clarification via email explaining the reasons for non-submission of the Outcome of the Board Meeting within 30 minutes/3 hours from the conclusion of the meeting, on December 4, 2025.

Thanking you,

Yours faithfully,

For **Maitreya Medicare Limited**

**Kashish Surana**  
**Company Secretary & Compliance Officer**

Maitreya Medicare Limited  
(Formerly known as "Maitreya Medicare Private Limited")

CIN - U24290GJ2019PLC107298

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30,  
2025

Notes to Unaudited standalone financial results

- 1 The above unaudited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on November 14, 2025.
- 2 The Results for the half year and year ended September 30, 2025 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 4 The figures for the half year ended September 30, 2025 limited reviewed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 5 The figures for the half-year ended September 30, 2024 are unaudited published figures in respect of the half-year ended September 30, 2024 limited reviewed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 6 The figures for the half-year ended March 31, 2025 are balancing figure between unaudited figures in respect of the half year ended september 30, 2024 limited reviewed by the statutory auditors and audited figures for the financial year ended March 31, 2025 .The comparative results for the year ended March 31, 2025 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2024 are audited published figures in respect of the year ended March 31, 2024 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 7 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- 8 During the year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.
- 9 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

Maitreya Medicare Limited  
(Formerly known as "Maitreya Medicare Private Limited")

CIN - U24290GJ2019PLC107298

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

Notes to Unaudited standalone financial results

S. No.	Object of the Issue	Allocated Amount (₹ in Thousands)	Amount utilised till September 30, 2025 (₹ in Thousands)	Amount unutilised till September 30, 2025 (₹ in Thousands)	Remarks (if any)
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	75,000.00	75,000.00	-	
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	10,000.00	9,600.00	400.00	Remaining amount is kept with banks.
3	Funding the working capital requirements of the company	50,000.00	50,000.00	-	
4	General Corporate Expenses	7,445.60	7,445.60	-	
5	Public Issue Expenses	6,466.40	6,466.40	-	
<b>Total</b>		<b>148,912.00</b>	<b>148,512.00</b>	<b>400.00</b>	

Place : Surat

Date : 14/11/2025

For MAITREYA MEDICARE LIMITED



NARENDRA TANWAR

DIN - 0008459007

Managing Director & CFO



**Maitreya Medicare Limited**  
(Formerly known as "Maitreya Medicare Private Limited")  
CIN - U24290GJ2019PLC107298

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

Particulars	Half year ended			For the year ended	For the year ended
	September 30, 2025	September 30, 2024	March 31, 2025	March 31, 2025	March 31, 2024
	Unaudited	Unaudited		Audited	Audited
I Revenue from operations	2,327.80	2,217.98	2,223.34	4,441.32	4,652.81
II Other income	14.09	14.28	29.70	43.98	22.27
III Total Revenue (I + II)	2,341.89	2,232.26	2,253.04	4,485.30	4,675.08
IV Expenses:					
(a) Cost of Raw Material Consumed	213.65	159.07	127.73	286.80	375.49
(b) Purchase of Stock-in-Trade	257.92	260.63	325.66	586.29	546.77
(c) Changes in inventories of stock-in-trade	-0.15	0.61	-1.65	(1.03)	26.64
(d) Employee benefits expense	250.47	243.55	278.32	521.88	475.19
(e) Finance costs	36.74	38.35	37.09	75.44	73.90
(f) Depreciation and amortization expense	71.47	63.46	71.14	134.59	125.59
(g) Other expenses	1,489.78	1,281.08	1,278.01	2,559.09	2,612.66
Total Expenses	2,319.86	2,046.75	2,116.50	4,163.06	4,236.24
V Profit before prior-period items and tax (III - IV)	22.03	185.51	136.74	322.25	438.85
VI Prior-Period Items					
VII Profit before tax (V - VI)	22.03	185.51	136.74	322.25	438.85
VIII Tax expense:					
(1) Current tax expense	5.73	49.77	30.99	80.75	119.94
(2) Deferred tax expense/(credit)	1.58	1.13	-	1.13	1.53
(3) Short/(Excess) provision of tax for earlier years			50.42	50.42	-
Dividend on Preference Shares	7.31	50.90	81.41	132.29	121.46
IX Profit from continuing operations (VII-VIII)	14.72	134.61	55.33	189.96	317.39
X Paid-up Equity Share Capital (Face Value of ₹ 10/- each)	677.60	677.60	677.60	677.60	677.60
XI Reserves excluding revaluation reserves as per balance sheet of previous accounting year					
XII Earnings per Equity Share (Non-Annualised) :- Face Value of ₹ 10/- each					
(Pre-bonus)					
- Basic	0.22	1.99	0.82	2.80	4.68
- Diluted					
(Post-bonus)					
- Basic					
- Diluted					

For MAITREYA MEDICARE LIMITED



NARENDRA TANWAR  
DIN - 0008459007  
Managing Director & CFO

Place : Surat  
Date : 14/11/2025

MAITREYA MEDICARE LIMITED  
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)  
UN AUDITED BALANCE SHEET AS ON 30th September 2025  
CIN No. - U24290GJ2019PTC107298

(Currency: Rs in '000')

Particulars	Note No.	As at 30th September 2025	As at 31st March 2025
<b>I. EQUITY &amp; LIABILITIES</b>			
<b>(1) Shareholders' Funds</b>			
a) Share capital	1	115523	120923
b) Reserve & Surplus	2	201314	199841
c) Money received against share warrants			
<b>(2) Share application money pending allotment</b>			
<b>(3) Non-Current Liabilities</b>			
a) Long-term Borrowings	3	12431	19594
b) Deferred tax liability (Net)	4	7111	6953
c) Other long term Liabilities			
d) Long term Provisions			
<b>(4) Current Liabilities</b>			
a) Short-term Borrowings	5	14634	15744
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises; and	6		2876
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.	6	31962	24937
c) Other current Liabilities	7	64850	45193
d) Short term Provisions	8	8649	8075
<b>Total</b>		<b>456474</b>	<b>444136</b>
<b>II. Assets</b>			
<b>(1) Non-current assets</b>			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	9	114506	118212
(ii) Intangible Assets		1297	1445
b) Non Current Investments	10	75730	75830
c) Deferred tax asset (net)			
d) Long term loans and advances	11	66683	52238
e) Other Non current assets	12	13096	12722
<b>(2) Current assets</b>			
a) Current Investments	13	422	422
b) Inventories	14	6862	4798
c) Trade receivables	15	140202	151850
d) Cash & Cash equivalents	16	29586	19090
e) Short-term loans and advances	17	4196	5019
f) Other current assets	18	3895	2510
<b>Total</b>		<b>456474</b>	<b>444136</b>
		<p>For MAITREYA MEDICARE LIMITED</p>  <p>NARENDRA TANWAR DIN - 0008459007 MD AND CFO 14th Nov 2025, Surat.</p>	

**MAITREYA MEDICARE LIMITED**  
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)  
**UN AUDITED PROFIT AND LOSS STATEMENT FOR THE PERIOD ENDED ON 30th September 2025**  
CIN No. - U24290GJ2019PTC107298  
(Currency: Rs in '000')

Particulars	Note No.	As at 30th September 2025	As at 31st March 2025
I. Revenue from operations	19	232780	444132
II. Other Income	20	1409	4398
<b>III. Total Income (I+II)</b>		<b>234189</b>	<b>448530</b>
<b>IV. Expenses:</b>			
Consumption of Stores and Pharmacy	21	21365	28680
Purchase of stock-in-Trade	22	25792	58629
Changes in inventories of finished goods, work-in-progress and stock-in-Trade	23	-15	-103
Employee benefit expense	24	25047	52188
Financial Costs	25	3674	7544
Depreciation and amortization expense	26	7147	13459
Other expense	27	148976	255909
<b>Total Expense</b>		<b>231985</b>	<b>416306</b>
<b>V. Profit Before exceptional and extraordinary items and tax</b>	(III-IV)	<b>2204</b>	<b>32224</b>
<b>VI. Exceptional Items</b>			
Adjustment of GST Liability			
Reversal of Previous Year Income Tax/TCS			
Rectification of Previous Year Mutual Fund Value			
Rectification of Depreciation			
Gratuity Prior Period			
Operating lease Prior Period Adjustment			
<b>VII. Profit Before extraordinary items and tax (V-VI)</b>		<b>2204</b>	<b>32224</b>
<b>VIII. Extraordinary Items</b>			
<b>IX. Profit before tax (VII-VIII)</b>		<b>2204</b>	<b>32224</b>
<b>X. Tax expense:</b>			
(1) Current Tax	28	573	8075
(2) Deferred Tax	29	158	113
(3) MAT Credit Entitlement			5042
(4) Income Tax Paid 2023-2024			
<b>XI. Profit/(Loss) from the period from continuing operations</b>		<b>1473</b>	<b>18993</b>
<b>XII. Profit/(Loss) from discontinuing operations</b>			
<b>XIII. Tax expense of discontinuing operations</b>			
<b>XIV. Profit/(Loss) from discontinuing operations (XII- XIII)</b>			
<b>XV. Profit/Loss for the period (XI+XIV)</b>		<b>1473</b>	<b>18993</b>
<b>XVI. Earning per equity share:</b>	30		
Basic		0.22	2.80
Diluted		0.22	2.80

For MAITREYA MEDICARE LIMITED



NARENDRA TANWAR  
DIN - 0008459007  
MB AND CFO  
14th Nov 2025, Surat.

**MAITREYA MEDICARE LIMITED**  
 [Formerly known as MAITREYA MEDICARE PRIVATE LIMITED]  
**UN AUDITED CASH FLOW STATEMENT**  
 CIN No. - U24290GJ2019PTC107298  
 (Currency: Rs In '000')

PARTICULARS	As at 30th September 2025		As at 31st March 2025	
		2204		32224
<b>A. Cash Flow from Operating Activities:</b>				
Profit Before exceptional and extraordinary items and tax Adjustments for :				
Depreciation	7147		13459	
Interest Income	-338		-695	
Gratuity	440		1677	
Interest & Finance Charges Paid	3674		7544	
Profit on sale of Investment			-225	
Sundry Balance Write back	244			
		11168		21761
Operating Profit before Working Capital Changes		13372		53985
Adjustments for :				
Increase / Decrease in Inventories	-2064		-113	
Increase / Decrease in Short-term loans and advances	824		-3478	
Increase / Decrease in Trade Receivables	11403		-21142	
Increase / Decrease in Trade Payables	4149		4312	
Increase / Decrease in other Current Assets	-1385		3312	
Increase / Decrease in other Non Current Assets	-814		4174	
Increase/Decrease in Provision	573		-3918	
Increase/Decrease in short term Borrowings	-1109		2143	
Increase/Decrease in other current liabilities	19657		25559	
Cash Generated from Operations		31234		10849
Direct Taxes Paid (Net)		44607		64834
<b>Net Cash Inflow in Operating Activities</b>		11319		14547
<b>B. Cash Flow from Investing Activities:</b>				
Purchases of Fixed assets	-3293		-23741	
Purchase of Investment	100		-44206	
Capital Government Grant of Fixed Assets				
Loans given to Associates and Subsidiaries	-3700		-9073	
Loans given to Others				
Repayment of Loans given to Associates and Subsidiaries				
Interest Income	338		695	
Gain on Sale of Investment				
Sale of Investment			4300	
<b>Net Cash used in Investing Activities</b>		-6555		-72026
		-6555		-72026
<b>Total A</b>		<b>33287</b>	<b>Total A</b>	<b>50287</b>
<b>Total B</b>			<b>Total B</b>	

<b>C. Cash Flow from Financing Activities:</b>			
Issue of Equity Capital			
Share Premium			
Dividend			
Issue of Preference Shares	-5400		
Redemption of Preference shares	-7164	-800	
Repayment of Borrowing	-3673	-7441	
Interest & Finance Charges Paid		-7544	
<b>Net Cash from Financing Activities</b>	<b>Total C</b>	<b>Total C</b>	<b>-15785</b>
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>	<b>Total (A+B+C)</b>	<b>Total (A+B+C)</b>	<b>-37524</b>
Opening Cash and Cash equivalents		19090	56614
<b>Closing Cash and Cash equivalents</b>		<b>29586</b>	<b>19090</b>

**Notes:**

- (i) Figures in brackets represent outflow.
- (ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act, 2013
- (iii) Cash and Cash Equivalents represent cash and bank balances.

For MAITREYA MEDICARE LIMITED



NARENDRA TANWAR  
DIN - 0008459007  
MD AND CFO  
14th Nov 2025, Surat.

Maitreya Medicare Limited  
(Formerly known as "Maitreya Medicare Private Limited")  
CIN - U24290GJ2019PLC107298

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025**

**Notes to Unaudited consolidated financial results**

- 1 The above unaudited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on November 14, 2025.
- 2 The Results for the half year and year ended September 30, 2025 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The results includes results of 2 wholly owned subsidiaries - Maitreya Hospital Private Limited and Maitreya Lifescience Private Limited and 1 subsidiary - Tulip Agility Private Limited.
- 4 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 5 The figures for the half year ended September 30, 2025 limited received by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 6 The figures for the half-year ended March 31, 2025 are balancing figure between unaudited figures in respect of the half year ended september 30, 2024 limited received by the statutory auditors and audited figures for the financial year ended March 31, 2025 .The figures for the half-year ended September 30, 2024 are unaudited published figures in respect of the half-year ended September 30, 2024 limited received by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 7 The comparative results for the year ended March 31, 2025 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2024 are audited published figures in respect of the year ended March 31, 2024 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 8 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- 9 During the preceding year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.

Maitreya Medicare Limited  
(Formerly known as "Maitreya Medicare Private Limited")  
CIN - U24290GJ2019PLC107298

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

Notes to Unaudited consolidated financial results

10 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

S. No.	Object of the Issue	Allocated Amount (₹ in Thousands)	Amount utilised till September 30, 2025 (₹ in Thousands)	Amount unutilised till September 30, 2025 (₹ in Thousands)	Remarks (if any)
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	75,000.00	75,000.00	-	Remaining amount is kept with banks.
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	10,000.00	9,600.00	400.00	
3	Funding the working capital requirements of the company	50,000.00	50,000.00	-	
4	General Corporate Expenses	7,445.60	7,445.60	-	
5	Public Issue Expenses	6,466.40	6,466.40	-	
<b>Total</b>		<b>148,912.00</b>	<b>148,512.00</b>	<b>400.00</b>	

For MAITREYA MEDICARE LIMITED

Place : Surat

Date : 14/11/2025



NARENDRA TANWAR

DIN - 0008459007

Managing Director & CFO




**Maitreya Medicare Limited**  
(Formerly known as "Maitreya Medicare Private Limited")

CIN - U24290GJ2019PLC107298

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

Particulars	Half Year ended			For the year ended	
	September 30, 2025	September 30, 2024	March 31, 2025	March 31, 2025	March 31, 2024
	Unaudited	Unaudited	Audited	Audited	Audited
I Revenue from operations	2,369.93	2,436.28	2,229.92	4,666.20	4,780.35
II Other income	22.98	18.98	38.23	57.22	27.22
III Total Revenue (I + II)	2,392.91	2,455.26	2,268.15	4,723.42	4,807.57
IV Expenses:					
(a) Cost of Raw Material Consumed	213.65	159.07	128.11	287.17	376.69
(b) Purchase of Stock-in-Trade	257.92	261.90	329.49	591.39	561.75
(c) Changes in inventories of stock-in-trade	4.14	4.66	-7.14	(2.48)	24.05
(d) Employee benefits expense	270.57	283.47	329.31	612.78	534.84
(e) Finance costs	42.89	45.10	35.11	80.20	84.24
(f) Depreciation and amortization expense	79.06	66.10	83.54	149.64	127.22
(g) Other expenses	1,519.61	1,408.75	1,280.57	2,689.12	2,711.71
Total Expenses	2,387.84	2,229.05	2,178.79	4,407.83	4,420.51
V Profit before prior-period items and tax (III - IV)	5.07	226.21	89.36	315.59	387.06
VI Prior-Period Items					
VII Profit before tax (V - VI)	5.07	226.21	89.36	315.59	387.06
VIII Tax expense:					
(1) Current tax expense	7.29	57.83	24.89	82.72	119.94
(2) Deferred tax expense/(credit)	1.39	1.15	-0.52	0.63	1.48
(3) Short/(Excess) provision of tax for earlier years	-	-	50.42	50.42	-
	8.68	58.98	74.79	133.78	121.42
IX Profit from continuing operations (VII-VIII)	(3.61)	167.23	14.57	181.81	265.64
X Minority Interest					
XI Profit attributable to owners of the equity (IX-X)	(3.61)	167.23	14.57	181.81	265.64
XII Paid-up Equity Share Capital (Face Value of ₹ 10/- each)	677.60	677.60	677.60	677.60	677.60
XIII Reserves excluding revaluation reserves as per balance sheet of previous accounting year					
XIV Earnings per Equity Share (Non-Annualised) :- Face Value of ₹ 10/- each					
(Pre-bonus)					
- Basic	-0.05	2.47	0.22	2.68	3.92
- Diluted					
(Post-bonus)					
- Basic					
- Diluted					

or MAITREYA MEDICARE LIMITED



NARENDRA TANWAR  
DIN - 0008459007  
Managing Director & CFO

Place : Surat  
Date : 14/11/2025

**MAITREYA MEDICARE LIMITED**  
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)  
**CONSOLIDATED UNAUDITED BALANCE SHEET AS ON 30th September 2025**  
CIN No. - U24290GJ2019PTC107298  
(Currency: Rs in '000')

Particulars	Note No.	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
		As at 30th September 2025	As at 31st March 2025
<b>I. EQUITY &amp; LIABILITIES</b>			
<b>(1) Shareholders' Funds</b>			
a) Share capital	1	115523	120923
b) Reserve & Surplus	2	199068	199428
c) Money received against share warrants	3		
d) Minorities Interest / Capital Reserve	3.1	7327	8227
<b>(2) Share application money pending allotment</b>			
<b>(3) Non-Current Liabilities</b>			
a) Long-term Borrowings	4	28180	36348
b) Deferred tax liability (Net)	5	7173	7034
c) Other long term Liabilities			
d) Long term Provisions			
<b>(4) Current Liabilities</b>			
a) Short-term Borrowings	6	14634	15744
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises; and small enterprises.	7	122	3295
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.		41884	28867
c) Other current Liabilities	8	69323	51805
d) Short term Provisions	9	9001	8272
<b>Total</b>		<b>492236</b>	<b>479943</b>
<b>II. Assets</b>			
<b>(1) Non-current assets</b>			
<b>(a) Property, Plant and Equipment</b>			
(i) Gross Block	10	237470	219621
(ii) Depreciation		74376	67024
(iii) Net Block		163094	152597
b) Non Current Investments	11	10	10
c) Deferred tax asset (net)			
d) Long term loans and advances	12	41569	30489
e) Other Non current assets	13	20296	18442
<b>(2) Current assets</b>			
a) Current Investments	14	422	422
b) Inventories	15	7558	5923
c) Trade receivables	16	144308	149565
d) Cash & Cash equivalents	17	82729	79163
e) Short-term loans and advances	18	27296	39789
f) Other current assets	19	4953	3542
<b>Total</b>		<b>492236</b>	<b>479943</b>

For MAITREYA MEDICARE LIMITED



NARENDRA TANWAR

DIN - 0008459007

MD AND CFO

14th, November, 2025, Surat

**MAITREYA MEDICARE LIMITED**  
**(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)**  
**Statement of Consolidated Un Audited Profit & Loss for the year ended 30th September 2025**  
**CIN No. - U24290GJ2019PTC107298**  
**(Currency: Rs In '000')**

Particulars	Note No.	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
		As at 30th September 2025	As at 31st March 2025
I. Revenue from operations	20	236993	466620
II. Other Income	21	2298	5722
<b>III. Total Revenue (I+II)</b>		<b>239291</b>	<b>472342</b>
<b>IV. Expenses:</b>			
Cost of materials consumed	22	21365	28717
Purchase of stock-in-Trade	23	25792	59139
Changes in inventories of finished goods, work-in-progress and stock-in-Trade	24	414	-248
Employee benefit expense	25	27057	61278
Financial Costs	26	4289	8020
Depreciation and amortization expense	27	7906	14964
Other expense	28	151961	268912
<b>Total Expense</b>		<b>238784</b>	<b>440783</b>
<b>V. Profit Before exceptional and extraordinary items and tax</b>	(III-IV)	<b>508</b>	<b>31559</b>
<b>VI. Exceptional Items</b>			
Adjustment of GST Liability			
Reversal of Previous Year Income Tax/TCS			
Rectification of Previous Year Mutual Fund Value			
Rectification of Depreciation			
Gratuity Prior Period			
Operating lease Prior Period Adjustment			
<b>VII. Profit Before extraordinary items and tax (V-VI)</b>		<b>508</b>	<b>31559</b>
<b>VIII. Extraordinary Items</b>			
<b>IX. Profit before tax (VII-VIII)</b>		<b>508</b>	<b>31559</b>
<b>X. Tax expense:</b>			
(1) Current Tax	29	729	8272
(2) Deferred Tax	30	139	63
(3) MAT Credit Entitlement			5042
(4) Income Tax Paid 2023-2024			
<b>XI. Profit(Loss) from the period from continuing operations</b>		<b>-360</b>	<b>18181</b>
<b>XII. Profit/(Loss) from discontinuing operations</b>			
<b>XIII. Tax expense of discontinuing operations</b>			
<b>XIV. Profit/(Loss) from discountinuing operations (XII- XIII)</b>			
<b>XV. Profit/Loss for the period (XI+XIV)</b>		<b>-360</b>	<b>18181</b>
<b>XVI. Earning per equity share:</b>	31		
Basic		<b>(0.05)</b>	<b>2.76</b>
Diluted		<b>(0.05)</b>	<b>2.76</b>

For MAITREYA MEDICARE LIMITED



NARENDRA TANWAR  
DIN - 0008459007  
MD AND CFO

14th, November, 2025, Surat

**MAITREYA MEDICARE LIMITED**  
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)  
Statement of Consolidated Un Audited Cash Flow Statement for the year ended 30th September 2025  
CIN No. - U24290GJ2019PTC107298  
(Currency: Rs in '000')

PARTICULARS	CONSOLIDATED AMOUNT	
	As at 30th September 2025	As at 31st March 2025
<b>A. Cash Flow from Operating Activities:</b>		
Net Profit before tax	508	32102
Adjustments for :		
Depreciation	7906	14421
Interest Income	-1159	-2154
Interest & Finance Charges Paid	4266	7984
Gratuity	440	1677
Profit on sale of Investment		275
Sundry Balance Write back	244	
<b>Sub Total</b>	<b>11697</b>	<b>22253</b>
Operating Profit before Working Capital Changes	12205	54253
Adjustments for :		
Increase / Decrease in Inventories	-1635	147
Increase / Decrease in Short-term loans and advances	824	-3478
Increase / Decrease in Trade Receivables	16994	-18444
Increase / Decrease in Trade Payables	-2136	6571
Increase / Decrease in Other Current Assets	9365	-619
Increase / Decrease in Other Non Current Assets	-794	4174
Increase / Decrease in Long-term loans and advances	-1500	145
Increase/Decrease in Provision	556	-3918
Increase/Decrease in short term liabilities	-1109	2143
Increase/Decrease in Current Liability	18249	24289
<b>Sub Total</b>	<b>38813</b>	<b>11009</b>
Cash Generated from Operations	51018	65264
Direct Taxes Paid (Net)	11475	14695
<b>Net Cash inflow in Operating Activities Total A</b>	<b>39543</b>	<b>50568</b>
<b>B. Cash Flow from Investing Activities:</b>		
Purchases of Property, Plant and Equipment	-18403	-23813
Purchase of Investment	100	-44656
Other bank Balance		
Capital Government Grant of Property, Plant and Equipment		
Loans given to Associates and Subsidiaries	-3700	-9073
Loans given to Others		
Loans received from Holding company		-2621
Interest Income	1159	2154
Gain on Sale of Investment		4300
Sale of Investment		
<b>Sub Total</b>	<b>-20844</b>	<b>-73709</b>
<b>Net Cash used in Investing Activities Total B</b>	<b>-20844</b>	<b>-73709</b>
<b>C. Cash Flow from Financing Activities:</b>		
Issue of Equity Capital		51600
Share application Money received	-100	
Share Premium		
Dividend		
Proceed of Borrowing	2696	4783
Issue of Preference Shares		
Redemption of Preference shares	-6300	-2000
Repayment of Borrowing	-7164	-9665
Interest & Finance Charges Paid	-4264	-7984
<b>Sub Total</b>	<b>-15132</b>	<b>36735</b>
<b>Net Cash from Financing Activities Total C</b>	<b>-15132</b>	<b>36735</b>
<b>Net Increase / (decrease) in cash and cash equivalents (A+B+C)</b>	<b>3567</b>	<b>13594</b>
Opening Cash and Cash equivalents	79164	65569
<b>Closing Cash and Cash equivalents</b>	<b>82730</b>	<b>79163</b>

**Notes:**

- (i) Figures in brackets represent outflow.  
(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act, 2013  
(iii) Cash and Cash Equivalents represent cash and bank balances.

For MAITREYA MEDICARE LIMITED



NAVINDRA TANWAR

DIN - 0008459007

MD AND CFO

14th, November, 2025, Surat



## UTILISATION CERTIFICATE OF ISSUE PROCEEDS

(Pursuant to NSE circular- Disclosure for Utilisation of Issue Proceeds)

To,

The Board of Directors,

**Maitreya Medicare Limited,**

(Formerly Known as Maitreya Medicare Private Limited)

CIN - U24290GJ2019PLC107298

### Registered Office:

Sai Palace, Nr. Someshwara Char Rasta,  
U.M. Road, Surat, Gujarat - 395007, India.

### Corporate Office:

Sai Palace, Nr. Someshwara Char Rasta,  
U.M. Road, Surat, Gujarat - 395007, India.

### Subject: Statutory Auditor's Certificate on Utilisation of Issue Proceeds.

We have examined the books of accounts and other relevant records of **Maitreya Medicare Limited** (formerly known as Maitreya Medicare Private Limited) for the purpose of certifying the utilisation of proceeds raised pursuant to the issue of equity shares, as disclosed in the Offer Document i.e., Prospectus dated November 01, 2023 for the period ended 30 September 2025.

This certificate is issued in accordance with **NSE Circular No. NSE/CML/2024/23** dated **September 05, 2024**, requiring disclosure of utilisation of issue proceeds by listed entities on the NSE EMERGE Platform.



Based on our examination of the records and according to the information and explanations given to us, we hereby certify that the issue proceeds have been utilised for period ended 30 September 2025 as detailed below:

**STATEMENT OF UTILISATION OF ISSUE PROCEEDS**

S. No.	Object of the Issue	Allocated Amount (in Thousands)	Amount utilised till September 30, 2025 (in Thousands)	Amount unutilised till September 30, 2025 (in Thousands)	Remarks (if any)
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	75,000.00	75,000.00	-	
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	10,000.00	9,600.00	400.00	Remaining amount is kept with banks.
3	Funding the working capital requirements of the company	50,000.00	50,000.00	-	
4	General Corporate Expenses	7,445.60	7,445.60	-	
5	Public Issue Expenses	6,466.40	6,466.40	-	
	<b>Total</b>	<b>148,912.00</b>	<b>148,512.00</b>	<b>400.00</b>	



**Certification:** We further certify that:

The utilisation of issue proceeds is in accordance with the objects stated in the Offer Document i.e. Prospectus dated November 01, 2023.

1. The unutilised amount of ₹ 400.00 thousands remains available with the Company.
2. There is no deviation or variation in the utilisation of issue proceeds.
3. The Company is not required to appoint a Monitoring Agency, and accordingly, this certificate is issued pursuant to the applicable NSE EMERGE provisions.
4. This certificate is issued after approval of the Audit Committee of the Company.

This certificate is issued for submission to the National Stock Exchange of India Limited (NSE EMERGE Platform) along with the financial results and for no other purpose.

For Saherwala & Co,  
Chartered Accountants  
Firm Registration No. 108969W



Esmayeel Oanali Saherwala  
Membership No. 122386  
UDIN: 26122386DLPLTR8733



Date: February 13, 2026

Place: Surat